◆ 会议时间：2024年12月11-13日
◆ 会议地点：瑞士 日内瓦/Geneva, Switzerland

◆ 会议简介：

2024年ESMO免疫肿瘤学大会将于2024年12月11-13日在瑞士日内瓦举行，会议由欧洲肿瘤内科学会（ESMO）组织。ESMO免疫肿瘤学大会是一个全球性会议，从免疫疗法的基础知识到最新的研究结果；从了解不同的治疗方案到毒性的管理和最新数据的解读，ESMO免疫肿瘤学大会将满足对癌症治疗这一热门领域感兴趣的肿瘤学利益相关者的不同需求。

欧洲肿瘤内科学会（ESMO）成立于1975年，是全球领先的肿瘤内科学专业组织。ESMO是肿瘤学教育和信息的参考学会，现在全球160多个国家和地区拥有超过25,000余名会员；ESMO致力于通过宣促进多学科的癌症护理，支持肿瘤学家的专业发展以及在全球倡导可持续的癌症护理，尽而为癌症患者提供最佳的护理。未经许可禁止复制摘录转载本站任何内容-国际医学会议网(lingyuint.com)

ESMO Immuno-Oncology Congress 2024

Date: 11-13 December 2024
Venue: Geneva, Switzerland

Organized by: European Society for Medical Oncology

The ESMO Immuno-Oncology Congress is a global meeting offering an advanced educational programme and the latest scientific developments in this promising field.

This international event provides an advanced educational programme and showcases recent scientific developments in this promising and fast-evolving field.

From the basics of immunotherapies to the latest research results; from understanding different treatment options to the management of toxicities and interpretation of new data, this event will cater to the diverse needs of oncology stakeholders with an interest in this topical field of cancer treatment.

Take part in this meeting to learn, share your research and expertise and connect with the stakeholders that are making a difference in the field.

摘要征文投稿：

Abstract submission deadlines

*A preliminary abstract indicating the data expected to be available by the LBA deadline must be submitted online by 26 September 2023 as an “intent to submit a late-breaking abstract”.

点此提交摘要>>>Submit Abstract>>

• ESMO I-O 2024 Abstract Regulations-提交指南

Outcome notifications

Outcome notifications of regular abstracts are expected to be made available to first authors and submitters by end-October 2024.

Outcome notifications of accepted full LBAs are expected to be made available to first authors and submitters by mid-Nov 2024.

Information for presenters

Detailed instructions for the preparation of slide presentations and/or posters will be made available by end-October in the section “Information for Presenters”. 

Abstract submission categories

• Biomarker development
• Cell therapy/Immune engineering
• Clinical practice
• Therapeutic development
• Tumour biology and tumour microenvironment
• Miscellaneous

Late-breaking abstracts

Late-breaking abstracts may be submitted for high quality, new research findings with implications for clinical practice or understanding of disease processes.

The final late-breaking abstract deadline of 6 November 2024 is under no circumstances to be considered as an extension of the general submission deadline (1 October 2024).

Trial in Progress abstracts

Trial in Progress (TiP) abstracts in all phases of clinical research (phases I to III) may be submitted to the ESMO Immuno-Oncology Congress 2024.

It is expected that abstracts submitted as Trial in Progress are ongoing trials that have not reached any protocol-specified endpoints for analysis.

Presentation and publication of accepted abstracts

The ESMO Immuno-Oncology Congress 2024 Scientific Committee will select abstracts for presentation during the Congress and determine the format of the presentations from the following possibilities:

• Proffered Paper – Oral presentations by authors presenting original data of superior quality, followed by expert discussion and perspectives. 
• Mini Oral – Short oral presentations by authors presenting data of good quality, followed by expert discussion and perspectives.
• Poster – Display session for review, discussion and questions. The presenting authors must be available onsite for Q&A to represent their work.

Accepted abstracts, including late-breaking abstracts, will be published online only in the ESMO Immuno-Oncology Congress 2024 Abstract Book, a supplement to the official ESMO journal, ESMO IOTECH.

Publication schedule of accepted abstracts

Details regarding the publication of accepted abstracts are available here.

ESMO Merit Travel Grant

A restricted number of ESMO Merit Travel Grants to the the ESMO Immuno-Oncology Congress 2024 are available, upon application, to first author (= presenter) who submit abstracts considered to be deserving of recognition. Candidates must be ESMO Members under the age of 40. Selection will be made by the the ESMO Immuno-Oncology Congress 2024 Scientific Committee on a competitive basis from among the accepted abstracts.

注册费：

Onsite participation includes:

• Participation in scientific and educational live sessions with the possibility to interact with the expert panel table
• Onsite networking opportunities with faculty and peers
• Entry to the Poster and e-Poster area
• Interaction with the industry partners in the trade exhibition
• Participation in the Industry Satellite Symposia
• Access to the Virtual Platform to view sessions missed on-demand
• Post-event resources
• Coffee breaks and lunches

Online participation includes:

• Access to the Virtual Platform, with live streaming of all sessions
• Possibility to interact through the chat live discussion
• Access to e-Posters
• Entry to the virtual exhibition
• Participation in the Industry Satellite Symposia
• Post-event resources

Please note that until 20 November 2024 an onsite registration can be changed to online and vice versa, at no additional charge.

Registration fees and deadlines

Individual registration will remain open for the duration of the meeting. The ESMO Congress Secretariat must receive one completed registration per participant and the corresponding payment in EUR by the given deadlines.

ESMO membership must be active seven (7) days prior to the registration deadline for the reduced member registration fee to be applied. Please visit membership page to check eligibility criteria, benefits, and to complete the membership application.

* Applicable to ESMO members from developing countries only.
At the time of application, developing countries are defined by ESMO according to the World Bank classification of low, lower-middle and upper-middle countries based on the Gross National Income (GNI) per capita. Download the PDF outlining which countries are eligible for the discounted registration fees.
**ESMO Members must be under 40 and in training to qualify for this fee.

Webcasts

The official sessions and Industry Satellite Symposia will be available on-demand on the Congress Virtual Platform until 16 December at 12:00 CET, for all registered participants.

Once the Congress Virtual Platform is closed, the on-demand content will be transferred to OncologyPRO.

Sessions from the official congress programme

Registered delegates and ESMO Members can access resources on OncologyPRO from 16 December 2024 for 2 years.

Satellite Symposia

Satellite Symposia webcasts will be available on OncologyPRO or ESMO website (only if permission has been granted by the Pharma Company) for ESMO members and registered delegates, from 16 December 2024 for 2 years.

Confirmation

By end-November 2024 delegates will receive the registration confirmation email and instructions on how to access the ESMO Immuno-Oncology Congress 2024.

Health & Safety

Health and safety measures at ESMO Immuno-Oncology Congress 2024 will be in place according to the latest local authority guidelines and requirements. Further information will be available on our website soon.

Travel insurance

ESMO requires recipients to purchase travel protection. Travel insurance is mandatory in order to protect delegates from the high cost of potential cancellation due to circumstances beyond the control of the congress organizer.
Adequate travel protection is also highly recommended for all congress participants as it protects travelers from risks like loss of passport or checked baggage and may offer coverage for unexpected medical expenses. Having these risks covered ensures an additional layer of protection against financial loss.

◆ 参会对象：：医生、医院科室主任/副主任、住院医师、医院管理者、医护人员以及从事该领域研究的科学家、研究人员、医药企业代表等等。